サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018

皮膚の熱傷、傷痕、および潰瘍薬剤開発パイプラインレビュー2018

レポート概要

本レポートは、皮膚の熱傷、傷痕、および潰瘍のパイプライン展望の概要を提供します。皮膚の熱傷、傷痕、および潰瘍の治療開発に関わる主要企業や開発中の治療法に関する包括的な情報を提供し、休止中および中止された製品を特徴としています。

褥瘡は、皮膚およびその下の組織を破壊する傷害です。身体のうち最も褥瘡を発症するリスクのある部分は、体脂肪が多くなく、支持面(ベッドまたは車椅子)と直接接触している部分です。原因には、連続的な圧力、摩擦、せん断が含まれ、治療には抗生物質や栄養が含まれます。この適応症の開発には6つの製品があります。

静脈下肢潰瘍は、足の静脈の高血圧が持続的に(静脈性高血圧)皮膚に損傷を与え、最終的に崩壊して潰瘍を形成するときに発症します。症状としては、加圧時に指の痕跡を一時的に保持する液体で満たされた膨らんだ足首(圧痕浮腫として知られる)、潰瘍の周囲の皮膚の変色および黒ずみ(ヘモジデロシス沈着症として知られる)、潰瘍周囲の硬化した皮膚 (脂肪性角質硬化症として知られる)、小さい赤い斑点を有している白い肌の小さな滑らかな領域(白色萎縮として知られる)があります。この適応症の開発には14の製品があります。

熱傷とは、熱、化学薬品、電気、太陽光、または放射線によって引き起こされる身体の組織の損傷を指します。症状には、熱傷の度合いとともに増す疼痛、赤く腫れた肌、水疱、焦げた黒っぽい肌が含まれます。治療には、抗生物質および鎮痛剤が含まれます。この適応症の開発には32の製品があります。

傷痕は傷の上に成長する恒久的な皮膚の斑点です。傷痕は組織損傷部位で起こり、赤紫色から紫色の線維組織にしっかりと現れ、通常は経時的により平滑で色が薄くなります。この適応症の開発には20の製品があります。

皮膚の熱傷、傷痕、および潰瘍のための開発中製品によって作用する分子標的は、インテグリン、インターロイキンおよび成長因子を含みます。このパイプライン領域で活動している企業には、MediWound社、Aegle Therapeutics社、NovaLead Pharma社が含まれます。

■調査範囲

  • 各パイプライン内において、最も活発に活動しているのはどの企業でしょうか?
  • 各適応症において、各開発段階で最も優れた薬物療法的アプローチはどれでしょうか?
  • このパイプライン内において、大学や組織は製薬企業と比べてどの程度重要な役割を果たすでしょうか?
  • この疾患分野において起きた最も重要なR&Dの画期的出来事や、データの公表は何でしょうか?

レポート詳細

目次

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Dermatological Burns, Scars and Ulcers Report Coverage
2.2 Pressure Ulcers - Overview
2.3 Venous Leg Ulcers (Crural Ulcer) - Overview
2.4 Burns - Overview
2.5 Scar - Overview

3 Therapeutics Development
3.1 Pressure Ulcers
3.2 Venous Leg Ulcers (Crural Ulcer)
3.3 Burns
3.4 Scar

4 Therapeutics Assessment
4.1 Pressure Ulcers
4.2 Venous Leg Ulcers (Crural Ulcer)
4.3 Burns
4.4 Scar

5 Companies Involved in Therapeutics Development
5.1 Pressure Ulcers
5.2 Venous Leg Ulcers (Crural Ulcer)
5.3 Burns
5.4 Scar

6 Dormant Projects
6.1 Pressure Ulcers
6.2 Venous Leg Ulcers (Crural Ulcer)
6.3 Burns
6.4 Scar

7 Discontinued Products
7.1 Pressure Ulcers
7.2 Venous Leg Ulcers (Crural Ulcer)
7.3 Burns
7.4 Scar

8 Product Development Milestones
8.1 Venous Leg Ulcers (Crural Ulcer)
8.2 Burns
8.3 Scar

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Number of Products under Development for Pressure Ulcers
Table 2: Number of Products under Development by Companies, Pressure Ulcers
Table 3: Products under Development by Companies, Pressure Ulcers
Table 4: Number of Products under Development for Venous Leg Ulcers (Crural Ulcer)
Table 5: Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer)
Table 6: Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer)
Table 7: Number of Products under Development for Burns
Table 8: Number of Products under Development by Companies, Burns
Table 9: Number of Products under Development by Universities/Institutes, Burns
Table 10: Products under Development by Companies, Burns
Table 11: Products under Development by Universities/Institutes, Burns
Table 12: Number of Products under Development for Scar
Table 13: Number of Products under Development by Companies, Scar
Table 14: Number of Products under Development by Universities/Institutes, Scar
Table 15: Products under Development by Companies, Scar
Table 16: Products under Development by Universities/Institutes, Scar
Table 17: Number of Products by Stage and Target, Pressure Ulcers
Table 18: Number of Products by Stage and Mechanism of Action, Pressure Ulcers
Table 19: Number of Products by Stage and Route of Administration, Pressure Ulcers
Table 20: Number of Products by Stage and Molecule Type, Pressure Ulcers
Table 21: Number of Products by Stage and Target, Venous Leg Ulcers (Crural Ulcer)
Table 22: Number of Products by Stage and Mechanism of Action, Venous Leg Ulcers (Crural Ulcer)
Table 23: Number of Products by Stage and Route of Administration, Venous Leg Ulcers (Crural Ulcer)
Table 24: Number of Products by Stage and Molecule Type, Venous Leg Ulcers (Crural Ulcer)
Table 25: Number of Products by Stage and Target, Burns
Table 26: Number of Products by Stage and Mechanism of Action, Burns
Table 27: Number of Products by Stage and Route of Administration, Burns
Table 28: Number of Products by Stage and Molecule Type, Burns
Table 29: Number of Products by Stage and Target, Scar
Table 30: Number of Products by Stage and Mechanism of Action, Scar
Table 31: Number of Products by Stage and Route of Administration, Scar
Table 32: Number of Products by Stage and Molecule Type, Scar
Table 33: Pressure Ulcers - Pipeline by EyeGene Inc
Table 34: Pressure Ulcers - Pipeline by Izun Pharmaceuticals Corp
Table 35: Pressure Ulcers - Pipeline by MimeTech Srl
Table 36: Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd
Table 37: Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc
Table 38: Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG
Table 39: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Daval International Ltd
Table 40: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Factor Therapeutics Ltd
Table 41: Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc
Table 42: Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc
Table 43: Venous Leg Ulcers (Crural Ulcer) - Pipeline by MallInckrodt Plc
Table 44: Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd
Table 45: Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd
Table 46: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB
Table 47: Burns - Pipeline by AlgiPharma AS
Table 48: Burns - Pipeline by Alliance Pharma Plc
Table 49: Burns - Pipeline by Amarantus Bioscience Holdings Inc
Table 50: Burns - Pipeline by CFM Pharma Holding BV
Table 51: Burns - Pipeline by Destiny Pharma Plc
Table 52: Burns - Pipeline by Energenesis Biomedical Co Ltd
Table 53: Burns - Pipeline by Madam Therapeutics BV
Table 54: Burns - Pipeline by MallInckrodt Plc
Table 55: Burns - Pipeline by MediWound Ltd
Table 56: Burns - Pipeline by Phagelux Inc
Table 57: Burns - Pipeline by Se-cure Pharmaceuticals Ltd
Table 58: Burns - Pipeline by Therapure Biopharma Inc
Table 59: Burns - Pipeline by USV Pvt Ltd
Table 60: Scar - Pipeline by Abzena Plc

1.2 List of Figures
Figure 1: Number of Products under Development for Pressure Ulcers
Figure 2: Number of Products under Development by Companies, Pressure Ulcers
Figure 3: Number of Products under Development for Venous Leg Ulcers (Crural Ulcer)
Figure 4: Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer)
Figure 5: Number of Products under Development for Burns
Figure 6: Number of Products under Development by Companies, Burns
Figure 7: Number of Products under Development for Scar
Figure 8: Number of Products under Development by Companies, Scar
Figure 9: Number of Products under Development by Universities/Institutes, Scar
Figure 10: Number of Products by Routes of Administration, Pressure Ulcers
Figure 11: Number of Products by Stage and Routes of Administration, Pressure Ulcers
Figure 12: Number of Products by Molecule Types, Pressure Ulcers
Figure 13: Number of Products by Stage and Molecule Types, Pressure Ulcers
Figure 14: Number of Products by Top 10 Targets, Venous Leg Ulcers (Crural Ulcer)
Figure 15: Number of Products by Stage and Top 10 Targets, Venous Leg Ulcers (Crural Ulcer)
Figure 16: Number of Products by Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer)
Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer)
Figure 18: Number of Products by Routes of Administration, Venous Leg Ulcers (Crural Ulcer)
Figure 19: Number of Products by Stage and Routes of Administration, Venous Leg Ulcers (Crural Ulcer)
Figure 20: Number of Products by Molecule Types, Venous Leg Ulcers (Crural Ulcer)
Figure 21: Number of Products by Stage and Molecule Types, Venous Leg Ulcers (Crural Ulcer)
Figure 22: Number of Products by Top 10 Targets, Burns
Figure 23: Number of Products by Stage and Top 10 Targets, Burns
Figure 24: Number of Products by Top 10 Mechanism of Actions, Burns
Figure 25: Number of Products by Stage and Top 10 Mechanism of Actions, Burns
Figure 26: Number of Products by Routes of Administration, Burns
Figure 27: Number of Products by Stage and Routes of Administration, Burns
Figure 28: Number of Products by Molecule Types, Burns
Figure 29: Number of Products by Stage and Molecule Types, Burns
Figure 30: Number of Products by Top 10 Targets, Scar
Figure 31: Number of Products by Stage and Top 10 Targets, Scar
Figure 32: Number of Products by Top 10 Mechanism of Actions, Scar
Figure 33: Number of Products by Stage and Top 10 Mechanism of Actions, Scar
Figure 34: Number of Products by Routes of Administration, Scar
Figure 35: Number of Products by Stage and Routes of Administration, Scar
Figure 36: Number of Products by Molecule Types, Scar
Figure 37: Number of Products by Stage and Molecule Types, Scar

発刊日

2018/09/28

体裁

PDF / 114ページ

販売価格

3,995USD

発行

GBI Research

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE